Hinge Health, Inc.
NYSE:HNGEMedical - Healthcare Information Services
-$0.24 today
- Market cap
- $9.31B
- Beta
- 1.99
- P/E (TTM)
- -10.3
- EPS (TTM)
- -$6.49
Volume 1.23M
Average 1.34M
HNGE Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Hinge Health, Inc.NYSE: HNGE
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $34.06M fell 87.8% year over year, behind the -63.1% change in trailing-twelve-month research & development. Sequentially, it rose 12.3% from the prior quarter.
Context
- Research & development amounted to 62.6% of revenue in FY2025, up 36.8 pp from a year earlier.
- Research & development increased in 1 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly growth recovers from -87.8% toward the trailing-twelve-month pace of -63.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 368.14M USD
- Year-over-year change
- +265.1%
- 2-year CAGR
- +82.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 368.14M | +265.1% |
| FY2024 | 2024-12-31 | 100.84M | -8.4% |
| FY2023 | 2023-12-31 | 110.06M | — |
Research & Development vs competitors
How HNGE compares with its peers on the latest reported figures
- HNGE's LTM Jun 2026 research & development of $129.07M is the 2nd highest of the 5 companies compared; the peer median is $77.97M.
- Its year-over-year change of -63.1% is the lowest of 4, against a peer median of +0.9%.
- Research & development amounts to 17.9% of revenue for HNGE, versus a peer median of 5.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $346M | +0.9% | +0.1% | 5.6% | |
| LTM Jun 2026 | $129.07M | -63.1% | — | 17.9% | |
| LTM Apr 2026 | $123.34M | +27.9% | +25.5% | 5.4% | |
| LTM Mar 2026 | $32.6M | -8.9% | +15.8% | 11.5% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding HNGE) | $77.97M | +0.9% | +15.8% | 5.5% | |
Competitors are the stored peer set for HNGE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 292.73M | 390.4M | 587.86M |
| Cost of Revenue | 98.55M | 89.81M | 118.56M |
| Gross Profit | 194.18M | 300.59M | 469.3M |
| Gross Margin | 66.3% | 77.0% | 79.8% |
| Research & Development | 110.06M | 100.84M | 368.14M |
| Selling, General & Admin | 214.64M | 227.54M | 639.41M |
| Operating Expenses | 324.69M | 332.5M | 1.02B |
| Depreciation & Amortization | 5.63M | 5.95M | 5.13M |
| EBITDA | (124.89M) | (18.48M) | (535.89M) |
| EBITDA Margin | -42.7% | -4.7% | -91.2% |
| Operating Income | (130.51M) | (31.91M) | (546.37M) |
| Operating Margin | -44.6% | -8.2% | -92.9% |
| Interest Income | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 21.97M | 20.65M | 19.11M |
| Income Before Tax | (108.55M) | (11.26M) | (527.26M) |
| Pre-Tax Margin | -37.1% | -2.9% | -89.7% |
| Income Tax Expense | (405K) | 677K | 998K |
| Net Income | (108.14M) | (11.93M) | (528.26M) |
| Net Margin | -36.9% | -3.1% | -89.9% |
| EPS (Basic) | (1.39) | (0.15) | (5.36) |
| EPS (Diluted) | (1.39) | (0.15) | (5.19) |
| Weighted Avg Shares | 78.02M | 78.02M | 79.19M |
| Weighted Avg Shares (Diluted) | 78.02M | 78.02M | 81.7M |
Hinge Health, Inc.
NYSE:HNGE
Intrinsic Alpha fair value
Locked
Current Price
$114.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.